- GlobeNewswire•7 days ago
NEW YORK, Sept. 23, 2016-- TG Therapeutics, Inc. today announced that Michael S. Weiss, the Company's Executive Chairman and Interim Chief Executive Officer, will present at the Ladenburg Thalmann 2016 ...
- GlobeNewswire•14 days agoTG Therapeutics, Inc. Announces Presentation of Data from a Phase Ib Clinical Trial of TG-1101 in Patients with Neuromyelitis Optica (NMO) at the 32nd Congress of the European Committee for Treatment and Research in Multiple Sclerosis
LONDON, Sept. 16, 2016-- TG Therapeutics, Inc. today announced the presentation of data from a Phase Ib open label study of TG-1101, the Company’ s novel, glycoengineered anti-CD20 monoclonal antibody, ...
- GlobeNewswire•last monthTG Therapeutics, Inc. Announces Clinical Data Presentation at the Upcoming 32nd Congress of the European Committee for Treatment and Research in Multiple Sclerosis
NEW YORK, Aug. 31, 2016-- TG Therapeutics, Inc., today announced that data from a Phase 1 b open label study of TG-1101 in acute relapses of neuromyelitis optica spectrum disorder, has been selected for ...
TG Therapeutics, Inc. (TGTX)
NasdaqCM - NasdaqCM Real Time Price. Currency in USD
|Bid||5.12 x 100|
|Ask||9.00 x 100|
|Day's Range||7.45 - 7.92|
|52wk Range||5.41 - 14.87|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||-5.93|
|Avg Vol (3m)||327,218|
|Dividend & Yield||N/A (N/A)|